Sequana Medical NV (EBR:SEQUA)

Market Cap	57.70M
Revenue (ttm)	105.50K
Net Income (ttm)	-44.65M
Shares Out	53.43M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	184,958
Average Volume	318,361
Open	1.054
Previous Close	1.088
Day's Range	1.036 - 1.080
52-Week Range	0.471 - 4.390
Beta	-0.05
RSI	48.95
Earnings Date	Jun 13, 2025

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Gent, B...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 48
• Stock Exchange: Euronext Brussels
• Ticker Symbol: SEQUA

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.